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ABSTRACT
Objective: To assess the cost-effectiveness of a
multifaceted quality improvement programme focused
on reducing central line-associated bloodstream
infections in intensive care units.
Design: Cost-effectiveness analysis using a decision
tree model to compare programme to non-programme
intensive care units.
Setting: USA.
Population: Adult patients in the intensive care unit.
Costs: Economic costs of the programme and of
central line-associated bloodstream infections were
estimated from the perspective of the hospital and
presented in 2013 US dollars.
Main outcome measures: Central line-associated
bloodstream infections prevented, deaths averted due
to central line-associated bloodstream infections
prevented, and incremental cost-effectiveness ratios.
Probabilistic sensitivity analysis was performed.
Results: Compared with current practice, the
programme is strongly dominant and reduces
bloodstream infections and deaths at no additional cost.
The probabilistic sensitivity analysis showed that there
was an almost 80% probability that the programme
reduces bloodstream infections and the infections’
economic costs to hospitals. The opportunity cost of a
bloodstream infection to a hospital was the most
important model parameter in these analyses.
Conclusions: This multifaceted quality improvement
programme, as it is currently implemented by hospitals
on an increasingly large scale in the USA, likely reduces
the economic costs of central line-associated
bloodstream infections for US hospitals. Awareness
among hospitals about the programme’s benefits
should enhance implementation. The programme’s
implementation has the potential to substantially reduce
morbidity, mortality and economic costs associated
with central line-associated bloodstream infections.
INTRODUCTION
Central line-associated bloodstream infec-
tions (CLABSI) are common, expensive to
payers and patients, and potentially fatal.1 2
Each year, nearly 80 000 Americans develop
CLABSIs in intensive care units (ICU), and
more than 25 000 of these patients die.3
A single infection can cost payers as much as
$56 000, culminating in over $2 billion in
related costs per year in the USA.4 CLABSIs
in ICU patients have an estimated attribut-
able mortality rate of 14–40%, with a pro-
longed length of stay of 7.5–25 days.5 6
The Keystone ICU project, ﬁrst launched
in Michigan in 2004 and since scaled across
the USA, Spain, Peru, Pakistan and the UK,
has captured the interest and attention of
patients, payers and policymakers for its sub-
stantial, sustained and scalable reductions in
preventable nosocomial infections. Over
1200 US hospitals are currently participating
in this multifaceted quality improvement pro-
gramme through On the CUSP: Stop BSI,
Strengths and limitations of this study
▪ This study was conducted according to best
practices in cost-effectiveness analysis and
demonstrates that a multifaceted quality improve-
ment programme can reduce the economic costs
of central line-associated bloodstream infections
for hospitals.
▪ We used nationally representative data sources to
increase generalisability and performed a prob-
abilistic sensitivity analysis to quantify the uncer-
tainty in our cost-effectiveness estimates.
▪ Owing to data limitations we were unable to
assess the impact of patient heterogeneity, such
as demographics and clinical characteristics, on
baseline risk, treatment effect or resource utilisa-
tion. We did not evaluate costs outside the acute
hospital setting, such as rehabilitation costs or
productivity losses for delays in returning to
work.
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a national collaborative, and many others are likely
using checklists and infection prevention programmes in
their ICUs as standard practice. The programme has
been evaluated through prospective cohort studies,7–10
retrospective observational studies using claims data,11
and both cluster non-randomised12 and randomised
controlled trials.13 When viewed collectively, this evi-
dence suggests that the programme is associated with
substantial reductions in CLABSIs and mortality in ICU
patients.
In spite of commendable investment in this pro-
gramme to manage the undesirable consequences of
CLABSIs, an important question remains unanswered:
compared with current practice, is this programme cost-
effective for US hospitals? Reporting of economic data
in quality improvement studies is uncommon, and there
are few formal cost-effectiveness analyses of quality
improvement programmes.14–16 Similarly, because the
estimated gross costs of CLABSIs to the healthcare
system are very high, the conclusion that expanding
infection control efforts will be cost saving (relative to
the costs incurred by expanded efforts) is accepted
without rigorous analysis.17 This paper examines the cost
changes and cost-effectiveness of the Keystone ICU
project from the perspective of the hospital using
nationally representative data sources from the USA.
METHODS
Overview of the analysis
We developed a decision tree model to address the
choice faced at an individual hospital about implement-
ing the programme (ﬁgure 1). The use of a decision
tree approach is justiﬁed by the short-term progression
of CLABSIs. The model assumes that patients do not
experience other adverse effects of catheterisation, such
as catheter colonisation leading to local infection, hyper-
sensitivity reactions or mechanical complications such as
pneumothorax. The Keystone ICU project instead
focused on infectious complications, because they are
more common, more costly and often fatal.18 Consistent
with other economic evaluations of CLABSIs in the ICU
setting, we assumed that the consequences of infection
are independent of age, patient disease severity and the
causative organism.18 19 These assumptions are congru-
ent with the programme itself, which does not discrimin-
ate between subgroups of patients based on these
factors.
The comparator was current practice as the most real-
istic alternative faced by organisations seeking to imple-
ment the programme. Current practice encompasses
on-going or existing activities that might inﬂuence the
risk of infection among patients, such as the use of anti-
infective central venous catheters.
The target population consisted of adult (18 years or
older) ICU patients in accordance with studies of the
Keystone ICU project and its subsequent replications.13
Since costs and beneﬁts only accrue while the pro-
gramme is implemented, the time frame and analytic
horizon are fundamentally the same. We used a time
horizon of 5 years. This analysis was performed from the
hospital’s perspective. Our study aims to address the fol-
lowing question: is implementation of this quality
improvement programme to decrease CLABSIs in the
ICU a cost-effective approach when compared with
current practice in US hospitals?
Quality improvement programme
Details of the programme and its conceptual approach
have been described elsewhere.20–22 In brief, this multi-
faceted programme employed clinician communication
tools, teamwork, and safety culture assessment and
improvement tools (known as the Comprehensive
Unit-based Safety Program (CUSP)), and a ﬁve-item,
evidence-based checklist for correctly inserting central
venous catheters. The ﬁve components of the checklist
included using basic hand hygiene, exercising full
barrier precautions, cleaning the skin with chlorhexi-
dine, avoiding the femoral site when possible, and
removing any unnecessary catheters. A model for
Figure 1 Decision tree model.
Decision tree model depicting
programme versus no programme
and its effects on outcomes in
intensive care unit (ICU) patients.
‘Bloodstream infections’ refers to
central line-associated
bloodstream infections.
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translating evidence into practice identiﬁed and miti-
gated local barriers to implementation of the checklist.22
Quarterly infection rates measured at the ICU level were
used to monitor progress towards the goal of reducing
CLABSIs.
Model inputs
Table 1 shows the key parameters used in the decision
tree model, such as probabilities and cost inputs as well
as the effectiveness of the programme, which are
described in detail in the following sections.
Risk of CLABSI and death
Estimates of the risk of CLABSI given exposure to a
central venous catheter varied from 3.0% to as much as
16.0%.23 24 We used a probability estimate of 5.2% for a
standard catheter, derived from a meta analysis of 13
randomised controlled trials from a previous economic
evaluation.18 25 Estimates of the attributable mortality of
CLABSI ranged from 14% to 40%.5 6 26 27 We used a
point estimate of 15%.
Costs
Estimates of payer costs attributable to CLABSI varied
widely, from as little as $6000 to over $56 000.4 6 18 28
The reasons for this variation can be attributed to the
small sample sizes of studies, challenges allocating
inpatient costs, perspectives used, the types of cost cat-
egories included, and the methodology used for estima-
tion.29 Existing studies have largely focused on ﬁnancial
costs (or hospital charges or payer costs) rather than
opportunity costs and so they may incorrectly estimate
the economic cost of CLABSIs to hospitals. We consid-
ered the economic cost of CLABSIs in terms of the
increased length of stay and the variable costs associated
with that occurrence.30 Given that a signiﬁcant amount
of hospital costs are ﬁxed in the short run, the eco-
nomic viability of quality improvement programmes that
reduce CLABSIs rests on two things: deploying the
bed-days freed by shorter lengths of stay for new admis-
sions and reducing utilisation of medications and sup-
plies. The value of the new admissions (the potential
incremental net revenue opportunity per prevented
infection) represents the economic cost of infection and
accordingly, the potential economic cost avoidance
resulting from infection prevention.31 Using this
approach, we estimated that the discounted cost of a
CLABSI was $18 793 (see online appendix tables A and
B for details of this calculation).
Start-up costs and recurring costs associated with the
quality improvement programme were assigned using an
activity-based microcosting of the programme performed
in six hospitals in Michigan.29 We assumed that start-up
costs occurred in the ﬁrst year of implementation and
did not discount them. Capital items, such as blood-
stream infection line carts, were annualised assuming a
5-year useful life and 3% discount rate. We included the
opportunity costs of key personnel whose time was com-
mitted to the programme even though a hospital may
not incur any ﬁnancial costs related to personnel who
are already on staff. We estimated this cost by multiply-
ing each staff person’s percentage effort committed to
the programme by an estimate of that position’s annual
compensation. We used the Society of Critical Care
Medicine’s annual compensation estimates from 2009
for critical care physicians, nurses, pharmacists and
respiratory therapists.32 The salary for infection control
preventionists was based on the Bureau of Labour
Statistics’s 2011 Occupational Employment Statistics and
we added 30% beneﬁts. Table 2 presents a detailed item-
isation of the start-up costs and recurring costs of the
programme. Start-up costs were approximately $80 000
and recurring costs were approximately $192 000 per
hospital per year. Personnel costs were the largest con-
tributor, comprising 95% of start-up costs and 89% of
recurring costs.
We estimated a per patient cost of the programme by
deriving an average number of ICU patients per hospital
who had central venous catheters (the patients most
likely to beneﬁt from the programme’s prevention
efforts). To calculate this, we ﬁrst derived a national
annual cohort of ICU patients exposed to central venous
catheters by multiplying the total annual ICU admissions
in the USA by an estimate of the proportion of patients
admitted to an ICU that receive central venous cathe-
ters.33 We then divided this group of ICU admissions with
central venous catheters by the number of hospitals that
reported having adult ICUs in the American Hospital
Association Annual Survey of Hospitals,34 yielding an
average number of ‘exposed’ patients per hospital.
Finally, we divided the total costs of the programme per
hospital by the number of patients per hospital to yield
an average cost for the programme per patient of $540
(SD, 120). Online appendix table C contains additional
Table 1 Parameters used in the decision tree model
Parameter Distribution Source
Probability of CLABSI* β: 0.052 (SD 0.0074) 18 25
Death attributable to
CLABSI
β: 0.15 (SD 0.056) 6
Incidence rate ratio of
programme versus
non-programme ICUs
Lognormal based on
normal mean 0.19
(SD 0.13)
13
Total cost$
CLABSI (per patient)† Lognormal based on
normal mean
$18 793 (SD 5533)
33
Programme
(per patient)†
Lognormal based on
normal mean $540
(SD 120)
29
*Conditional probability of a CLABSI given exposure to a central
venous catheter, assumes standard (non-antimicrobial) catheter.
†Discounted costs presented.
CLABSI, central line-associated bloodstream infection; ICU,
intensive care unit.
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details of this calculation, including the uncertainty
ranges incorporated into the estimate.
All costs were adjusted to 2013 US dollars using the
consumer price index for medical care services.
Recurring costs were discounted by 3% annually. In sep-
arate sensitivity analyses, we examined the effect of not
discounting costs and of discounting costs by 5%.
Effectiveness
We based our estimate of the programme’s effectiveness
on a cluster randomised controlled trial that found an
81% reduction in CLABSI rates comparing programme
ICUs with control ICUs (incidence rate ratio, 0.19; 95%
CI 0.06 to 0.57).13 We used the CI of this point estimate,
a measure of uncertainty in the programme’s effective-
ness, to derive a SD of the estimate for probabilistic sen-
sitivity analysis. This effectiveness parameter was
measured at the ICU level but in our model we assumed
that it applied to individual patients. This ecological
assumption was necessary because there are no patient
level effectiveness estimates available from the Keystone
ICU project. The SD of the estimate captures the hetero-
genic reality that the intervention beneﬁt is not uniform
among ICU patients.
To calculate the base case probability of a CLABSI in
the programme arm of the decision tree, we multiplied
the probability of CLABSI by the incidence rate ratio
(0.19) from the trial. We assumed that by the end of the
ﬁrst year of implementation, programme ICUs achieve
this reduction. The original ICUs that implemented the
programme maintained the reduction for the subse-
quent 10 years (Sam Watson, written communication, 18
August 2013). We assumed this to be true for the 5-year
period used in this evaluation.35
The number of annual ICU admissions requiring
catheters, the probability of infection and the
attributable mortality parameters were assumed not to
change during the 5-year period.
Outcome measures
The two outcomes of interest were CLABSIs prevented
and deaths averted (lives saved). We calculated the
number of CLABSIs prevented as the difference in the
number of CLABSIs between programme and non-
programme ICUs. Deaths averted were calculated simi-
larly. We did not discount CLABSIs or deaths in the base
case analysis to avoid making the ethically challenging
assumption that infections or deaths prevented in the
future are worth less than they are in the present. We
explored the effect of discounting CLABSIs and deaths
by 3% in a sensitivity analysis.
We calculated incremental cost-effectiveness ratios as
the additional cost divided by the additional health
beneﬁt (CLABSIs prevented or deaths averted) compar-
ing the programme to current practice.
Probabilistic sensitivity analyses
We conducted a probabilistic sensitivity analysis to
account for uncertainty in the model’s input parameters.
We used Monte Carlo simulation to perform 10 000
iterations of the model, simultaneously sampling each
parameter from an underlying distribution that reﬂects
the degree of uncertainty in the parameter estimate.
Uncertainty in parameter estimates was obtained from
the CIs or SDs published with the point estimates.
Table 1 presents the modelled distributions, point esti-
mates and SDs for the key model parameters. All ana-
lyses were performed using Microsoft Excel (Microsoft
Corporation; Redmond, Washington, USA) with @Risk
(Palisade Corporation; Ithaca, New York, USA).
Table 2 Itemisation of programme costs (per hospital)
Cost category Start-up costs Recurring costs
Personnel$
Critical care physicians (2 on average per hospital) $26 004 $71 953
Nurses (8 on average per hospital) $44 406 $75 306
Respiratory therapists $4605 $7923
Infection control preventionists $1981 $7855
Pharmacists $2725 $7962
Education and Training$
Education and training expenses $3579
Capital items$
CLABSI line cart/central line insertion cart (annual equivalent cost) $426 $426
Materials$
Chlorhexidine $2378
Oral care kits $6933
Sterile central line dressing kits $11 555
Total$ $83 725 $192 292
Recurring costs occur each year that the intervention is in place; as such, this total represents the annual recurring cost (not discounted as
presented here).
CLABSI, central line-associated bloodstream infection.
4 Herzer KR, et al. BMJ Open 2014;4:e006065. doi:10.1136/bmjopen-2014-006065
Open Access
group.bmj.com on January 26, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
RESULTS
Table 3 compares programme and non-programme ICU
costs and outcomes for CLABSIs prevented and deaths
averted. The quality improvement programme prevents
42 CLABSIs per 1000 patients and averts 6 deaths per
1000 patients at no additional cost in the base case ana-
lysis, representing a dominant strategy when compared
with current practice.
Figure 2 and online supplementary ﬁgure S1 show the
cost-effectiveness planes comparing the joint density of
incremental costs and incremental effects for 10 000
model iterations. Incremental refers to the difference in
costs or effects between programme and non-
programme ICUs. The X-axis represents the incremental
level of effectiveness of an outcome and the Y-axis repre-
sents the additional total cost of achieving this outcome.
Each data point in the scatterplot represents an esti-
mated incremental cost-effectiveness ratio for the
outcome; as such, the scatterplot illustrates the distribu-
tion of incremental cost-effectiveness ratios over a
sample population. Points falling to the right of the
Y-axis demonstrate that the programme is effective for
preventing CLABSIs and averting deaths. Points falling
above the X-axis represent the additional costs of the
programme and points falling below the X-axis repre-
sent the economic cost savings from the programme. In
ﬁgure 2, because 80% of the points fall below the
X-axis, there is an 80% probability that the programme
reduces bloodstream infections and the infections’ eco-
nomic costs to hospitals compared with current practice.
Figure 2 also demonstrates the presence of few extreme
values (outlier incremental cost-effectiveness ratios) in
the model, indicating little uncertainty in the estimates
of the quality improvement programme’s cost-
effectiveness compared with current practice. Outliers
add variability and uncertainty to the overall cost-
effectiveness results and the existence of few such
Table 3 Comparison of costs and outcomes between programme and non-programme ICUs
Mean Median 2.5th–97.5th centile
Non-programme ICU
CLABSIs 52 52 39–66
Deaths 8 8 2–14
Costs* $987 000 $937 000 $488 000–$1 760 000
Programme ICU
CLABSIs 10 9 3–29
Deaths 2 1 0–5
Costs$* $738 000 $710 000 $453 000–$1 190 000
Benefit of programme†
CLABSIs prevented 42 42 23–58
Deaths averted 6 6 2–12
Net costs$ −$249 000 −$221 000 −$976 000 to $300 000
Incremental cost-effectiveness ratio (probability)
Cost per CLABSI prevented Strongly dominant (0.80)‡
Cost per death prevented Strongly dominant (0.80)‡
Mean, median, 2.5% and 97.5% centile estimates for outputs from probabilistic sensitivity analysis of 10 000 model runs representing
uncertainty in epidemiological and economic parameters are reported.
All mean, median, and centile values are expressed per 1000 patients to make the scale easier to interpret. Values have been rounded to
three significant digits at most.
*Costs are not presented separately for each outcome (CLABSI and death) because no additional cost was assumed to occur for death;
discounted at 3%.
†Benefit of programme determined by subtracting programme ICU estimates from non-programme ICU estimates within the model.
‡Probability that the programme is more effective and less costly than current practice.
CLABSI, central line-associated bloodstream infection; ICU, intensive care unit.
Figure 2 Cost-effectiveness plane for central line-associated
bloodstream infections prevented with 95% confidence
ellipses. Values on both axes have been multiplied by 1000 to
yield incremental costs and effects expressed per 1000
patients to aid interpretation. Incremental refers to the
difference in costs or effects between programme and
non-programme intensive care units. Cost values in US
dollars. Boxes in the plot region display the percentage of the
distribution of incremental cost-effectiveness ratios falling
above or below $0. The 95% confidence ellipses overlaid on
the figure are calculated assuming a bivariate normal
distribution and display the uncertainty in the incremental
costs-effectiveness ratios.
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outliers in the cost-effectiveness plane supports the
robustness of the programme as a dominant strategy.
Online supplementary ﬁgures S2 and S3 display
tornado diagrams of the results of the probabilistic sensi-
tivity analysis. The opportunity cost of CLABSIs exerted
the largest inﬂuence on the cost-effectiveness of the pro-
gramme for preventing CLABSIs and deaths. As such,
hospitals implementing the programme should know
the opportunity costs they face due to CLABSIs. The
opportunity cost is calculated as the potential incremen-
tal net revenue opportunity per prevented CLABSI. We
provide an example of how to perform this calculation
in the online appendix. Discounting CLABSIs or deaths
at 3% in addition to costs, does not change the inter-
pretation of our results. Similarly, discounting costs at
0% or 5% does not change the interpretation of our
ﬁndings (see online appendix table D).
DISCUSSION
This study represents the ﬁrst formal cost-effectiveness
analysis of a nationally implemented quality improve-
ment programme (the Keystone ICU project) in the
USA to decrease CLABSIs in critically ill patients. One
of the few large scale quality improvement projects to
demonstrate long-term sustainability, this programme
has the potential to reduce CLABSIs and deaths at no
additional cost to US hospitals.
Comparison with other studies
Previous studies highlight the importance and difﬁculty
of developing a business case for quality improvement.
A business case exists if healthcare organisations invest-
ing in an intervention reap a return on their invest-
ment.36 Many prevention initiatives have suffered from a
lack of evidence supporting a positive return on invest-
ment for hospitals and payers.37 Incentive misalignment
results in hospitals incurring costs to implement quality
improvement programmes while payers accrue the sub-
sequent cost savings. A ﬁnancial analysis of a replication
of the Keystone ICU project in one tertiary hospital in
Hawaii demonstrated that reducing CLABSIs actually
resulted in lower proﬁt margins, thus creating a perverse
incentive to provide a lower quality of care.38 A different
study calculated that, for every CLABSI prevented, the
programme costs $5404,29 and suggested that it is cost
saving when compared with the cost of an infection
(which ranges from $6000 to over $56 0004 6 33 39 40).
However, both studies used inaccurate cost analyses that
focused on the ﬁnancial rather than the economic costs
of CLABSIs. These studies also did not account for
uncertainty in the cost or effect estimates.
Our evaluation offers several improvements to these
existing studies. First, whenever possible we used nation-
ally representative data to determine provider salary and
compensation costs, so as to increase the ability to gener-
alise our ﬁndings. Second, we performed a probabilistic
sensitivity analysis to quantify the uncertainty in our cost-
effectiveness estimates. Third, we considered the oppor-
tunity costs of CLABSIs rather than ﬁnancial costs. Our
estimate of the cost of a CLABSI is based on the fore-
gone hospital revenue that results whenever an infection
occurs. From the perspective of the hospital, reducing
the cost of CLABSIs is tantamount to reducing this fore-
gone revenue by redeploying ICU beds for new admis-
sions. Finally, we extended the evaluation to consider
deaths prevented as an additional outcome because of
its interest to clinicians and patients.
Limitations of the study
This evaluation has several limitations. First, the impact
of patient heterogeneity, such as demographics and clin-
ical characteristics on baseline risk, treatment effect or
resource utilisation was not fully explored.41 This evalu-
ation sought instead to represent an average ICU experi-
ence, in part because the data needed to explore
subgroups are not available, but more importantly
because the intervention applies to patients irrespective
of these differences. It would be impractical—and pos-
sibly unethical—to only use this programme in sub-
groups of patients for whom greater beneﬁt is expected.
The programme is based on evidence-based practices
for inserting central venous catheters—practices that
should apply equally to all patients. Second, we did not
evaluate costs outside the acute hospital setting, such as
rehabilitation costs or productivity losses for delays
returning to work incurred by patients suffering
CLABSIs. However, doing so would further support the
cost-effectiveness of the programme. We chose to
examine costs from the perspective of the hospital
because hospitals bear the greatest burden of nosoco-
mial infection costs in the prospective payer system and
demonstrating a business case is important for the dis-
semination of effective quality improvement pro-
grammes. Finally, this evaluation did not explore the use
of antimicrobial catheters as an comparator because sys-
tematic reviews have come to differing conclusions
about the extent of their effectiveness in preventing
CLABSIs, and many of the trials have been small and of
a low quality.42 43 In addition, the choice facing hospital
decision makers is not necessarily a mutually exclusive
choice between the Keystone ICU project or the use of
antimicrobial catheters. The results of Keystone ICU
project already reﬂect the use of various types of cathe-
ters because the programme itself did not specify cath-
eter type. The parameter estimate for effectiveness of
the programme used in this evaluation was derived from
a cluster randomised controlled trial. In this setting it
can be expected that the utilisation of antimicrobial
catheters should be balanced between the intervention
and control arms of the trial (though this was not expli-
citly measured), and the effectiveness estimate is attrib-
utable to the quality improvement programme itself.
The Keystone ICU project quality improvement pro-
gramme is also a complex social intervention.
Comparing it directly to technology or a device
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understates its broader effects, which may include reduc-
tions in sepsis and ventilator-associated pneumonia or
reduced staff turnover resulting from an improved safety
culture.21 Data for these effects are limited in compari-
son to the data available for CLABSIs, but recent evi-
dence suggests that the Keystone ICU project
signiﬁcantly reduced rates of ventilator -associated pneu-
monia in Michigan ICUs.9 Inclusion of these additional
beneﬁcial effects for the same set of costs would further
support the cost-effectiveness of the programme.
Conclusions and implications of study findings
These ﬁndings have important implications for health-
care. Broad implementation of the Keystone ICU project
in the US healthcare system could substantially reduce
the morbidity and mortality associated with CLABSIs
and their economic costs to hospitals. Although the
Centers for Disease Control and Prevention has demon-
strated that signiﬁcant reductions in CLABSIs are
indeed being realised for intensive care patients in the
USA,44 800 medium and large hospitals continue to
have high CLABSIs rates.45 Further dissemination of
cost-effective quality improvement programmes is
needed. Although our analysis adopted a hospital per-
spective, payers also stand to beneﬁt from the pro-
gramme and can support dissemination efforts.
Hospitals and payers should partner to reform the
incentive structure facing hospitals in order to better
support patient safety and quality. Payer support, such as
covering or funding some intervention costs and impos-
ing ﬁnancial penalties on hospitals when patients
develop CLABSIs, could encourage uptake and dissem-
ination of the programme. Future evaluations of this
quality improvement programme in non-US settings can
incorporate country-speciﬁc costs or extend the evalu-
ation to consider additional outcomes, such as cases of
ventilator-associated pneumonia prevented. As more
data and evidence emerges regarding the long-term
costs and outcomes for patients with CLABSI and other
healthcare associated infections,46 future economic eva-
luations can incorporate this information to gauge the
cost-effectiveness of prevention and quality improvement
efforts.
To conclude, this multifaceted quality improvement
programme, currently being implemented by thousands
of hospitals in the USA, likely reduces unnecessary mor-
bidity, mortality and economic costs associated with
CLABSIs.
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